| Name | TD139 |
| Description | TD139 is a small molecule inhibitor of inhaled galectin-3 (Gal-3) with potential anti-fibrotic activity, commonly used in the study of idiopathic pulmonary fibrosis. |
| In vitro | TD139 has a high affinity for galectin-3 with a Kd of 14 nM and 10 nM for galectin-1, but low affinity for galectins 2, 4N, 4C, 7, 8N, or 9N [1]. |
| In vivo | In primary lung AECs, TD139 reduces TGF-β1–induced β-catenin translocation to the nucleus, keeping most β-catenin at the cell surface, and blocks TGF-β1–induced β-catenin phosphorylation. TD139 treatment in WT mice results in a marked reduction in lung fibrosis and β-catenin activation, along with decreased galectin-3 expression [1]. Pretreatment of WT C57BL/6 mice with TD139 attenuates liver injury, reduces infiltration of IFNγ-, IL-17-, and IL-4-producing CD4(+) T cells, increases IL-10-producing CD4(+) T cells and F4/80(+) CD206(+) alternatively activated macrophages, and prevents apoptosis of liver-infiltrating MNCs [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : Insoluble
Ethanol : 3 mg/mL
DMSO : 55 mg/mL (84.79 mM)
|
| Keywords | TD-139 | TD 139 | TD139 |
| Inhibitors Related | G3-C12 acetate(848301-94-0 free base) | Galectin-3 antagonist 2 | Thiodigalactoside | Galectin-3/galectin-8-IN-1 | Galectin-3/galectin-8-IN-2 | GB1107 | DB21, Galectin-1 Antagonist | OTX008 |
| Related Compound Libraries | 非甾体类抗炎化合物库 | 经典已知活性库 | ReFRAME 相关化合物库 | 药物功能重定位化合物库 | 抑制剂库 | 抗纤维化化合物库 | NO PAINS 化合物库 | 临床期小分子药物库 | 已知活性化合物库 | 抗代谢疾病化合物库 |
United States
